Celgene profit tops estimates on strong cancer drug sales
July 25 (Reuters) - Biotechnology firm Celgene Corp reported a quarterly profit above analysts' estimates as demand for its cancer drugs, Revlimid and Abraxane, remained strong, and the company raised its full-year earnings forecast for the second time.
Second-quarter net income rose to $478.1 million, or $1.11 per share, from $367.4 million, or 82 cents per share, a year earlier.
Excluding one-time items, it earned $1.52 per share. Analysts on average expected a profit of $1.44 per share, according to Thomson Reuters I/B/E/S.
- Housing, jobs data weaken, but overall economic picture still upbeat
- U.S. diplomats, but not prosecutors, seek to quell India dispute |
- Target cyber breach hits 40 million payment cards at holiday peak |
- New York Mayor-elect's reputation for lateness parodied on Twitter
- Last-minute Obamacare exemption for those with canceled plans